

MATERIALS LICENSE

Amendment No. 08

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302434

Licensee

In accordance with letter dated
March 7, 1997

1. Memorial Hospital of Burlington

3. License Number 48-18803-01 is amended
in its entirety as follows:2. 252 McHenry Street
Burlington, WI 53105-0257

4. Expiration Date November 30, 2000

5. Docket or
Reference No. 030-141896. Byproduct, Source, and/or
Special Nuclear Material7. Chemical and/or Physical
Form8. Maximum Amount that Licensee
May Possess at Any One Time
Under This LicenseA. Any byproduct
material identified
in 10 CFR 35.100A. Any
radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct
material identified
in 10 CFR 35.200B. Any
radiopharmaceutical
identified in 10 CFR
35.200 (excluding
xenon-133)

B. As needed

C. Any byproduct
material identified
in 10 CFR 35.300C. Any
radiopharmaceutical
identified in 10 CFR
35.300

C. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

C. Medical use described in 10 CFR 35.300.

CONDITIONS

10. Location of Use: 301 Randolph Street, Burlington, WI 53103-0257.

11. Radiation Safety Officer: Gilbert S. Wadina, M.D.

9704140014 970408
PDR ADDCK 03014189
C PDR

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

48-18803-01

Docket or Reference Number

030-14189

Amendment No. 08

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|----------------------------|--|
| A. Lee H. Huberty, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| B. Gregory Gullo, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| C. Gilbert S. Wadina, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| D. Kenneth E. Clark, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| E. Lawrence J. Reif, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| F. John Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| G. Robert J. Swoboda, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300. |
| H. Donald J. Kash, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| I. E. L. Koch, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| J. Jane Cary Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| K. James Aceto, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| L. Mary Beth Barr, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| M. L. Samuel Wann, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133), limited to clinical cardiovascular procedures. |

13. The licensee shall follow the procedures in Appendix O of Reg. Guide 10.8 when using Tc-99m aerosols.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

48-18803-01

Docket or Reference Number

030-14189

Amendment No. 08

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received May 30, 1990; and
- B. Letters dated May 18, 1994 (excluding authorization request for Dr. James Aceto and request for material in 10 CFR 35.300 (excluding thyroid carcinoma) for Dr. Carrie Pallin), June 5, 1996 and March 7, 1997.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

APR 08 1997

By

Loren J. Hunter

Nuclear Materials Licensing Branch, Region III

COPY

R8

(FOR LFMS USE)
INFORMATION FROM LTS

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

Program Code: 02120
Status Code: 0
Fee Category: 7C
Exp. Date: 20001130
Fee Comments:
Decon Fin Assur Req'd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: MEMORIAL HOSPITAL OF BURLINGTON
Received Date: 970319
Docket No: 3014189
Control No.: 302434
License No.: 48-18803-01
Action Type: Amendment

2. FEE ATTACHED

Amount: 440
Check No.: 002472

3. COMMENTS

Signed D. Hersey
Date 3-28-97

2. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered ☒)

1. Fee Category and Amount: 7C \$440

2. Correct Fee Paid. Application may be processed for:

Amendment _____
Renewal _____
License _____

3. OTHER _____

Signed SC
Date 3/25/97

APR 01 1997

Log	Mar 9 7U
Remitter	
Check No.	82492
Amount	\$440
Fee Category	7C
Type of Fee	AmD
Date Check Rec'd	3/21/97
Date Completed	3/25/97
By	SC

1997 MAR 21 PM 1:22

MEMORIAL HOSPITAL OF BURLINGTON
252 Mc Henry Street
Burlington, WI 53105-0257

March 7, 1997

U. S. Nuclear Regulatory Commission
Region III
Licensing Section
801 Warrenville Road
Lisle, Illinois 60532-4351

RE: Amendment to Radioactive Materials License #48-18803-01

Dear Sir or Madam:

Please amend the above referenced radioactive materials license to reflect the following:


1. We would like to move our Nuclear Medicine Department within the hospital. Attached is a diagram as to the new location within the hospital. Also attached is a diagram of the new Hot Lab and Imaging Room. We will complete a close-out survey on the existing area prior to releasing it for unrestricted use. We would like to move during the middle of April.
2. Please add L. Samuel Wann, M.D. to our license as an authorized user of materials identified in 10 CFR 35.100 and 35.200. Dr. Wann is currently listed on materials license #48-26600-01 (copy attached).

Enclosed is a check for \$440.00 to cover the cost of processing this amendment.

We would appreciate timely processing of our requests because we want to move in the very near future.

If you have any questions regarding this information, please call Sue Harris at our facility.

Sincerely,





Paul Miller
Chief Executive Officer
:gob

RECEIVED
MAR 19 1997
REGION III

Pm: 3-17-97


MAR 19 1997

302434




MAIN ENTRANCE
DROP OFF AREANEW
VESTIBULEEXISTING
VESTIBULEREVOLVING
DOOR

BENCH

Hospital
Entrance

Nuc. Med.

01/08/97



MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301035

Licensee 1. Aurora Health Center	In accordance with letters dated October 17, 1995, November 30, 1995 and February 2, 1996 3. License Number 48-26600-01 is amended in its entirety as follows:
2. 10400 75th Street Kenosha, WI 53142	4. Expiration Date October 31, 2004 5. Docket or Reference No. 030-33637

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
---	----------------------------------	--

A. Any byproduct material identified in 10 CFR 35.100

A. Any radiopharmaceutical identified in 10 CFR 35.100 (excluding sodium iodide I-131 and I-125 greater than 30 microcuries)

A. As needed

B. Any byproduct material identified in 10 CFR 35.200

B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133, generators and sodium iodide I-131 and I-125 greater than 30 microcuries)

B. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133, generators and sodium iodide I-131 and I-125 greater than 30 microcuries).

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at Aurora Health Center, 10400 75th Street, Kenosha, WI 53142.

COPY

NRC Form 374A
(5-64)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

48-26600-01

Docket or Reference number

030-33637

Amendment No. 02

11. A. Radiation Safety Officer: Mack A. Karnes, M.D.
B. Alternate Radiation Safety Officer: Daniel Rapp, M.D.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users ..Material and Use

A. Mack A. Karnes, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

B. Charles K. Hellman, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries), limited to clinical cardiovascular procedures.

C. L. Samuel Wann, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries), limited to clinical cardiovascular procedures.

D. Keith G. Bernard, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

E. Werner Kordas, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

F. Lawrence Dubin, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

G. Jill Stevens, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

H. Steven C. Port, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

I. David Slosky, M.D.

10 CFR 35.100 and 35.200 (excluding xenon-133 and sodium iodide I-131 and I-125 greater than 30 microcuries).

APR 08 1997

Paul Miller, CEO
Memorial Hospital of Burlington
252 McHenry Street
Burlington, WI 53105-0257

Dear Mr. Miller:

Enclosed is Amendment No. 08 to your NRC Material License No. 48-18803-01 in accordance with your request.

This amendment authorizes you to move your Nuclear Medicine Department to the new location within your hospital, as requested.

Please be advised that we cannot authorize you to release your old nuclear medicine space for unrestricted use (even by other members of your staff) until we have received and reviewed a copy of the results of your close-out survey. The survey should consist of exposure rate measurements to show that all sources of radioactive material have been removed, and contamination checks of areas where radioactive materials were used or stored. Average radiation levels associated with surface contamination and removable contamination should not exceed those specified in the enclosed decontamination guide. Please submit the following information with your close-out survey:

- a. A diagram of your old facility with survey and wipe test results keyed to specific locations.
- b. The name of the person performing the survey.
- c. The date the survey was performed.
- d. The instrument(s) used for exposure rate measurements and for analysis of the wipes.
- e. Background readings.
- f. The date that the survey instrument was last calibrated.

Please provide the above information as additional information to Control No. 302434 to preclude an additional amendment fee and request that we expedite the amendment authorizing release of your old nuclear medicine space for unrestricted use.

302434

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
 - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
 - a. When you decide to terminate all activities involving materials authorized under the license; or
 - b. If you decide not to complete the facility, acquire equipment, or possess and use authorized material.
4. Request and obtain a license amendment before you:
 - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
 - b. Permit anyone, except individuals described in 10 CFR 35.13(b) to work as an authorized user under the license;
 - c. Change Radiation Safety Officers;

- d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
 - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
 - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Loren J. Hueter
Nuclear Materials Licensing Branch

License No. 48-18803-01
Docket No. 030-14189

Enclosures: 1. Amendment No. 08
2. NRC Form 313

DOCUMENT NAME: M:\03014189.CL7

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII	<input checked="" type="checkbox"/>						
NAME	LJHueter:brt	<i>LJH</i>						
DATE	04/07/97							

OFFICIAL RECORD COPY

CONVERSATION RECORD

TIME

DATE

4-4-97

☐ VISIT☐ CONFERENCE☒ TELEPHONE☐ INCOMING☒ OUTGOING

NAME OF PERSON(S) CONTACTED OR IN CONTACT

ORGANIZATION (OFFICE, DEPT. ETC.)

TELEPHONE NO.

Julie Elvin, RTR

Mem. Hosp. of
Burlington

414-

763-0369

SUBJECT

CN 302434

SUMMARY

1. Julie confirmed that the "Main Entrance Drop off area" at the Hospital entrance on the map submitted with March 7, 1997 letter, does not refer to a drop off for delivery of nuclear materials. They are always brought directly to the Nuc. Med. Lab.

Julie says they never used I-125 and last use of I-131 was in February, about 2 weeks ago and they will not be using any more until after they move which is planned to occur in May. She also confirmed that there is no sink in lab to be vacated. We discussed the need for a second amendment to release the old lab based on a close-out survey & to request an expedite & ref

CN 302434.

ACTION REQUIRED

NAME OF PERSON DOCUMENTING CONVERSATION

SIGNATURE

DATE

Loren Hunter

4-4-97

ACTION TAKEN

SIGNATURE

TITLE

DATE